stoxline Quote Chart Rank Option Currency Glossary
Century Therapeutics, Inc. (IPSC)
1.476  0.016 (1.1%)    11-29 10:11
Open: 1.48
High: 1.535
Volume: 16,019
Pre. Close: 1.46
Low: 1.43
Market Cap: 88(M)
Technical analysis
2023-11-29 10:17:35 AM
Short term     
Mid term     
Targets 6-month :  1.91 1-year :  2.17
Resists First :  1.63 Second :  1.86
Pivot price 1.4
Supports First :  1.27 Second :  1.06
MAs MA(5) :  1.48 MA(20) :  1.46
MA(100) :  2.17 MA(250) :  3.46
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  32.1 D(3) :  33.5
RSI RSI(14): 48.6
52-week High :  10.94 Low :  1.27
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IPSC ] has closed below upper band by 29.6%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.48 - 1.49 1.49 - 1.5
Low: 1.35 - 1.36 1.36 - 1.37
Close: 1.44 - 1.46 1.46 - 1.47
Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Thu, 09 Nov 2023
Century Therapeutics, FUJIFILM Cellular Dynamics Expand Cell ... - Contract Pharma

Thu, 09 Nov 2023
Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results - Yahoo Finance

Thu, 02 Nov 2023
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition - Yahoo Finance

Sun, 09 Jul 2023
Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 10% this week, taking one-year losses to 70% - Simply Wall St

Wed, 12 Apr 2023
Century Therapeutics CEO Lalo Flores steps down (NASDAQ:IPSC) - Seeking Alpha

Wed, 08 Feb 2023
Century Therapeutics Announces First Patient Dosed in First-In ... - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 60 (M)
Held by Insiders 2.166e+007 (%)
Held by Institutions 37.7 (%)
Shares Short 684 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1554e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -21 %
Return on Assets (ttm) 368.9 %
Return on Equity (ttm) -17.6 %
Qtrly Rev. Growth 2.49e+006 %
Gross Profit (p.s.) -124.41
Sales Per Share -62.59
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -85 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0.3
Stock Dividends
Dividend 0
Forward Dividend 842910
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android